β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer

Piera Tocci, Roberta Cianfrocca, Valeriana Castro, Laura Rosanò, Andrea Sacconi, Sara Donzelli, Silvia Bonfiglio, Gabriele Bucci, Enrico Vizza, Gabriella Ferrandina, Giovanni Scambia, Giovanni Tonon, Giovanni Blandino () and Anna Bagnato ()
Additional contact information
Piera Tocci: Regina Elena National Cancer Institute
Roberta Cianfrocca: Regina Elena National Cancer Institute
Valeriana Castro: Regina Elena National Cancer Institute
Laura Rosanò: Regina Elena National Cancer Institute
Andrea Sacconi: IRCCS, Regina Elena National Cancer Institute
Sara Donzelli: IRCCS, Regina Elena National Cancer Institute
Silvia Bonfiglio: San Raffaele Scientific Institute
Gabriele Bucci: San Raffaele Scientific Institute
Enrico Vizza: IRCCS, Regina Elena National Cancer Institute
Gabriella Ferrandina: Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of Rome
Giovanni Scambia: Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of Rome
Giovanni Tonon: San Raffaele Scientific Institute
Giovanni Blandino: IRCCS, Regina Elena National Cancer Institute
Anna Bagnato: Regina Elena National Cancer Institute

Nature Communications, 2019, vol. 10, issue 1, 1-15

Abstract: Abstract The limited clinical response observed in high-grade serous ovarian cancer (HG-SOC) with high frequency of TP53 mutations (mutp53) might be related to mutp53-driven oncogenic pathway network. Here we show that β-arrestin1 (β-arr1), interacts with YAP, triggering its cytoplasmic-nuclear shuttling. This interaction allows β-arr1 to recruit mutp53 to the YAP-TEAD transcriptional complex upon activation of endothelin-1 receptors (ET-1R) in patient-derived HG-SOC cells and in cell lines bearing mutp53. In parallel, β-arr1 mediates the ET-1R-induced Trio/RhoA-dependent YAP nuclear accumulation. In the nucleus, ET-1 through β-arr1 orchestrates the tethering of YAP and mutp53 to YAP/mutp53 target gene promoters, including EDN1 that ensures persistent signals. Treatment of patient-derived xenografts reveals synergistic antitumoral and antimetastatic effects of the dual ET-1R antagonist macitentan in combination with cisplatinum, shutting-down the β-arr1-mediated YAP/mutp53 transcriptional programme. Furthermore, ETAR/β-arr1/YAP gene signature correlates with a worst prognosis in HG-SOC. These findings support effective combinatorial treatment for repurposing the ET-1R antagonists in HG-SOC.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-11045-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11045-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-11045-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().